N/A
N=36
A Double Blind Clinical Trial of DCS for Food Anxiety
Anorexia and Bulimia Nervosa
Bottom Line
View on ClinicalTrials.gov: NCT01996644 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcome: Primary: Anxiety as Measured by the Subjective Units of Distress (Ranging From 1 to 100). — 52.395; 58.983 Units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Placebo vs Setraline (Drug); Setraline (Drug)
- Age
- Pediatric, Adult, Older Adult · 14+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- Feb 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Anxiety as Measured by the Subjective Units of Distress (Ranging From 1 to 100). |
52.395; 58.983 | — |
| PRIMARY Body Mass Index |
.385; .095 | .043 sig |
Summary
This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be reduced more in the DCS relative to placebo condition (c) participants in the DCS condition will have a greater increase in Body Mass Index.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise Specified
Exclusion Criteria
- Pregnant or planning on becoming pregnant
- Psychotic or Manic
Data sourced from ClinicalTrials.gov (NCT01996644). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.